ASAttila Szijártó

Attila Szijártó

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Attila Szijártó has a total of 78 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Hypocalcemia on Admission Is a Predictor of Disease Progression in COVID-19 Patients with Cirrhosis: A Multicenter Study in Hungary

    by Bálint Drácz, Veronika Müller, István Takács, Krisztina Hagymási, Elek Dinya, Pál Miheller, Attila Szijártó, Klára Werling

    Hypocalcemia is a common condition in liver cirrhosis and is associated with the severity of SARS-CoV-2 infection. However, there is a lack of data demonstrating the prognostic value of hypocalcemia in COVID-19 patients with cirrhosis. This study aimed to evaluate the prognostic value of hypocalcemia for COVID-19 severity, mortality and its associations with abnormal liver function parameters. We selected 451 COVID-19 patients in this retrospective study and compared the laboratory findings of 52 COVID-19 patients with cirrhosis to those of 399 COVID-19 patients without cirrhosis. Laboratory tests measuring albumin-corrected total serum calcium were performed on admission, and the levels were monitored during hospitalization. The total serum calcium levels were significantly lower in cirrhosis cases (2.16 mmol/L) compared to those without cirrhosis (2.32 mmol/L). Multivariate analysis showed that hypocalcemia in COVID-19 patients with cirrhosis was a significant predictor of in-hospital mortality, with an OR of 4.871 (p < 0.05; 95% CI 1.566–15.146). ROC analysis showed the AUC value of total serum calcium was 0.818 (95% CI 0.683–0.953, p < 0.05), with a sensitivity of 88.3% and a specificity of 75%. The total serum calcium levels showed a significant negative correlation with the Child–Turcette–Pugh score (r = −0.400, p < 0.05). Hypocalcemia on admission was a significant prognostic factor of disease progression in COVID-19 patients with cirrhosis.


  • Open Access

    Effectiveness of COVID-19 Vaccination with mRNA Vaccines for Patients with Cirrhosis in Hungary: Multicentre Matched Cohort Study

    by Bálint Drácz, Veronika Müller, István Takács, Krisztina Hagymási, Elek Dinya, Pál Miheller, Attila Szijártó, Klára Werling

    Patients with cirrhosis are vulnerable to hepatic decompensation events and death following COVID-19 infection. Therefore, primary vaccination with COVID-19 vaccines is fundamental to reducing the risk of COVID-19 related deaths in patients with cirrhosis. However, limited data are available about the effectiveness of mRNA vaccines compared to other vaccines. The aim of our study was to investigate the efficacy of mRNA vaccines versus other vaccines in cirrhosis. In this retrospective study, we compared clinical characteristics and vaccine effectiveness of 399 COVID-19 patients without cirrhosis (GROUP A) to 52 COVID-19 patients with cirrhosis (GROUP B). 54 hospitalised cirrhosis controls without COVID-19 (GROUP C) were randomly sampled 1:1 and matched by gender and age. Of the cirrhosis cases, we found no difference (p = 0.76) in mortality rates in controls without COVID-19 (11.8%) compared to those with COVID-19 (9.6%). However, COVID-19 patients with cirrhosis were associated with higher rates of worsening hepatic encephalopathy, ascites and esophageal varices. Patients with cirrhosis receiving mRNA vaccines had significantly better survival rates compared to viral vector or inactivated vaccines. Primary vaccination with the BNT162b2 vaccine was the most effective in preventing acute hepatic decompensating events, COVID-19 infection requiring hospital admission and in-hospital mortality.


  • Open Access

    Prognostic Ability of Tumor Budding Outperforms Poorly Differentiated Clusters in Gastric Cancer

    by Luca Szalai, Ákos Jakab, Ildikó Kocsmár, Ildikó Szirtes, István Kenessey, Attila Szijártó, Zsuzsa Schaff, András Kiss, Gábor Lotz, Éva Kocsmár

    The prognostic value of histological phenomena tumor budding (TB) and poorly differentiated clusters (PDCs) have been less studied in gastric cancer (GAC) and the data provided so far are controversial. In our study, 290 surgically resected GAC cases were evaluated for TB according to the criteria of International Tumor Budding Consensus Conference (ITBCC) and PDC, and both parameters were scored on a three-grade scale as described for colorectal cancer previously (0: Grade0, 1–4: Grade1, 5–9: Grade2 and ≥10: Grade3) and classified as low (Grade0–2) and high (Grade3) TB/PDC. High TB/PDC was associated with diffuse-type morphology, higher pT status, incomplete surgical resection, poor tumor differentiation and perineural and lymphovascular invasion. Multivariable survival analyses have shown an independent prognostic role of high TB with poorer overall survival in the total cohort (p = 0.014) and in intestinal-type adenocarcinomas (p = 0.005). Multivariable model revealed high TB as an independent predictor for lymph node metastasis in both the total cohort (p = 0.019) and in the intestinal type adenocarcinomas (p = 0.038). In contrast to tumor budding, no significant association was found between PDC and the occurrence of lymph node metastasis and tumor stage and even survival. In conclusion, tumor budding is an independent prognostic factor of survival in gastric cancer, especially in intestinal-type adenocarcinomas.


  • Open Access

    A focalis nodularis hyperplasia multimodális kezelése

    by Damján Pekli, Bálint Kokas, Dávid Bárdos, András Fülöp, Péter Pajor, Oszkár Hahn, Ildikó Illyés, Attila Kovács, Attila Szijártó

    Összefoglaló. A focalis nodularis hyperplasia (FNH) a máj második leggyakrabban előforduló benignus góca. Nem malignizálódik, így a jelenlegi ajánlások szerint eltávolítása relatív indikációt képez. Kezelését illetően több különböző módszer is ismert. A közlemény célja, hogy összefoglalót adjon az FNH ellátásáról és két esetben bemutassa az alternatív kezelési lehetőségeket. Egy 40 éves nőbetegnél hasi panaszok miatt indult kivizsgálás során a májban CT-morfológiailag FNH igazolódott. A laesio lokalizációját figyelembe véve, a sebészeti reszekció magas rizikója miatt, transarterialis embolisatio (TAE) mellett döntöttünk. Többszörös kezelést követően a kontroll képalkotó vizsgálatok alapján jelentős regressziót értünk el, mindemellett a beteg panaszmentessé vált. Egy 25 éves nőbetegnél hasi panaszok miatt történt MR-vizsgálat igazolt FNH-t. Az elhelyezkedésre tekintettel TAE-t végeztünk, a beteg azonban ezúttal nem vált teljesen panaszmentessé. Definitív megoldásként májreszekció történt, melyet követően panaszai megszűntek. Tünetmentes FNH felfedezésekor elegendő lehet a betegek hosszú távú követése. Tünetek, illetve nagy műtéti kockázat esetében a malignus májtumoroknál rutinszerűen alkalmazott TAE az FNH-ban akár önmagában vagy sebészi kezeléssel kombinálva is eredményesen alkalmazható. Kisebb rizikó esetén a legmegfelelőbb választás a primer laparoszkópos reszekció. Orv Hetil. 2022; 163(15): 606–612. Summary. Focal nodular hyperplasia (FNH) is the second most common benign mass of the liver. According to the current recommendations, removal makes relative indication. Several different treatment methods are known. The purpose of the paper is to provide a summary of FNH care and to present alternative treatment options in two cases. A 40-year-old woman was investigated for abdominal complaints; CT scan confirmed FNH of the liver. Given the localization of the lesion, we chose transarterial embolization (TAE) due to the high risk of surgical resection. After multiple treatments, regression was achieved, and the patient became asymptomatic. Painful FNH in a 25-year-old female was confirmed by MRI. The lesion was dominantly seen in segment 1, causing vena cava compression and collaptiform episodes. As a definitive solution, liver resection was performed, after which her complaints ceased. Long-term follow-up of patients may be sufficient when asymptomatic FNH is detected. In the case of symptoms or high risk of surgery, TAE can be used effectively by FNH either alone or in combination with surgical treatment. For lower-risk patients, primary laparoscopic resection is the most appropriate choice. Orv Hetil. 2022; 163(15): 606–612.


  • Open Access

    Colorectalis májmetastasisok komplex kezelése. Konszenzuskonferencia, Budapest, 2019. április 5.

    by Semmelweis Egyetem Magyar Hepato-Pancreatico-Biliaris (Hpb) Kutatócsoport, Csilla András, Péter Bartek, István Battyáni, János Bezsilla, György Bodoky, Barna Bogner, Attila Bursics, Tibor Csőszi, László Damjanovich, et al.